The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis
- 1 September 2002
- journal article
- research article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 130 (1-2) , 163-172
- https://doi.org/10.1016/s0165-5728(02)00225-4
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Effects of Linomide on immune cells and cytokines inhibit autoimmune pathologies of the central and peripheral nervous systemInternational Immunopharmacology, 2001
- Immunologic Therapy of Multiple SclerosisAnnual Review of Medicine, 1999
- Linomide suppresses acute experimental autoimmune encephalomyelitis in Lewis rats by counter-acting the imbalance of pro-inflammatory versus anti-inflammatory cytokinesJournal of Neuroimmunology, 1998
- Linomide Enhances Apoptosis in CD4+CD8+ ThymocytesScandinavian Journal of Immunology, 1997
- Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitisProceedings of the National Academy of Sciences, 1997
- Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosisNeurology, 1996
- Linomide inhibits programmed cell death of peripheral T cells in vivoEuropean Journal of Immunology, 1994
- Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomideAnnals of Neurology, 1993
- Changes in hypothalamic corticotrophin-releasing factor and anterior pituitary pro-opiomelanocortin mRNA during the course of experimental allergic encephalomyelitisJournal of Neuroimmunology, 1993
- Chronic experimental autoimmune encephalomyelitis induced by the 89‐101 myelin basic protein peptide in B10RIII (H-2r) miceEuropean Journal of Immunology, 1991